Tag Archives: AIDS

Medicines Patent Pool: Industry's Toe Still in the Water

At a time when Big Pharma is struggling with new business models geared to the demands of a changing marketplace, the Medicines Patent Pool (MPP) is offering a way forward through voluntary licensing and patent deals that it insists will deliver what the drug majors say they want: more innovation; better market access; and the […]
Posted in healthcare, IP | Also tagged , , , | Leave a comment

US Cuts Could Jeopardize Global Health Innovations, Says Report

Cuts to US global health and research programs for diseases such as AIDS, tuberculosis and malaria risk derailing the innovations crucial to fighting these diseases, according a new report by the Global Health Technologies Coalition.
Posted in Events | Also tagged , , , , | Leave a comment

AIDS: ARV Optimism Tempered by Home Truths

The prospect that antiretroviral drugs could prevent HIV infection in high-risk populations was the big news emerging from last month’s International AIDS Conference in Washington, DC. But the news raises the tricky ethical question of whether the US should spend $11,000 per patient to keep uninfected individuals healthy, when funds are lacking to provide life-saving […]
Posted in FDA, Guest Blog, healthcare | Also tagged , , , , , , | Leave a comment

Challenges in the March Toward an AIDS-Free Generation

FDA’s approval of Truvada, a once-a-day oral combination of tenofovir and emtricitabine, for pre-exposure prophylaxis (or PrEP, a method for preventing HIV infection) arrived during a chorus of optimism surrounding major developments in the fight against AIDS.
Posted in Biotech, Events, FDA, healthcare, Market Access, Patient Communication, patient compliance, patient education, pricing, Regulatory, Safety | Also tagged , , , , , , | Leave a comment

TB Alliance Trumpets New, Improved Drugs at World Health Assembly

Like polio and leprosy, developed countries have long since tamed tuberculosis. But even now, other parts of the world continue to struggle against the disease, with nearly all (98 percent) of TB’s 1.7 million worldwide deaths occurring in developing countries. TB’s high comorbidity with HIV infections has recently added another level of urgency to efforts […]
Posted in Corporate Responsibility, Emerging Markets, Global, R&D | Also tagged , , , , , , , , , | Leave a comment
  • Categories

  • Meta